Ozempic manufacturer Novo Nordisk said patient safety is a priority and “the benefit-risk profile of semaglutide remains ...

Food companies fatten us up only for Big Pharma to let us inject ourselves slim again. Crazy? Perhaps it’s the beginning of ...

Hims sells a compounded version of Novo Nordisk's (NVO) semaglutide, the active ingredient in Wegovy and Ozempic for, ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The high cost of health care drove the vast majority of strategies in the benefits space, as pharmacy benefit managers found ...

That's why Novo Nordisk's shares are worth sticking with for good, and at about $108 apiece, investors can afford two of them ...

Notable deals and regulatory reviews concern Merck's obesity drug initiative, the first U.S. severe bird flu case, and ...

GLP-1 medications are a class of drugs, made popular by Novo Nordisk’s (NVO+0.13%) diabetes drug Ozempic, that mimic a ...

The agency, which oversees Medicare plans for people aged 65 and older or with disabilities, said healthcare spending ...

By licensing a drug from Hansoh, Merck signaled that it isn’t prepared to fully challenge its rivals' dominance in the GLP-1 ...

Health-care companies fell, but not by as much as the broad market, as traders rotated into sectors less sensitive to interest-rate moves. The European Union's drug regulator said it would review two ...

Nestle is launching protein shots in the United States which it says help suppress appetite for people looking to shed pounds ...